EGFR与HER-2在不同分子类型乳腺癌中的表达及其相关性分析

doi:10.3969/j.issn.1004-616x.2022.02.008

摘要/Abstract

摘要： 目的：探讨EGFR和HER-2在不同分子类型乳腺癌组织中的表达及其相关性。方法：回顾性分析2015年1月—2020年3月在邯郸市中心医院行手术治疗的乳腺癌患者资料650例(其中浸润性导管癌600例，浸润性小叶癌50例)及乳腺纤维腺瘤30例，应用免疫组织化学(IHC)方法对手术切除标本进行EGFR和HER-2蛋白表达检测，采用χ²检验及Spearman相关分析对数据进行统计学分析。结果：EGFR在乳腺浸润性导管癌中表达阳性率为48.7%，显著高于浸润性小叶癌(24.0%)及纤维腺瘤(16.7%)(P<0.01)。HER-2在乳腺浸润性导管癌中表达阳性率为27.8%，显著高于浸润性小叶癌(8.0%)及纤维腺瘤(6.7%)(P=0.002)。乳腺浸润性导管癌与浸润性小叶癌中，EGFR阳性率与HER-2评分等级呈正相关(r=1.000，P<0.05)，且EGFR阳性率与HER-2阳性表达呈正相关(r=1.000，P<0.05)。EGFR阳性率在HER-2过表达型与三阴型乳腺癌组织中显著高于Luminal A型和Luminal B型，且Luminal B中HER-2阳性显著高于HER-2阴性亚型(P<0.001)。结论：EGFR、HER-2阳性率在乳腺浸润性导管癌显著升高，且EGFR阳性率与HER-2的评分等级及阳性表达率均呈正相关，EGFR在HER-2过表达型与三阴型乳腺癌组织中显著升高，为进一步研究HER-2阳性乳腺癌及三阴型乳腺癌的靶向药物治疗提供线索及理论依据。

关键词: 乳腺癌, 浸润性导管癌, 人类表皮生长因子受体, 人类表皮生长因子受体2, 免疫组化

Abstract: OBJECTIVE： To investigate expression and correlation of EGFR and HER-2 in different types of breast cancer tissues. METHODS：A retrospective analysis of 650 cases of breast cancer (600 cases of invasive ductal carcinomas， 50 cases of invasive lobular carcinoma) and 30 cases of fibroadenoma was conducted at the Surgery Treats in Handan Central Hospital from Jan. 2015 to Mar. 2020. Expression of EGFR and HER-2 were detected in 650 cases of breast cancers and 30 cases of fibroadenomas via routine detection of EGFR and HER-2 proteins by immunohistochemical method. χ² test and Spearman correlation analyses were used for statistical analysis of the data，and P<0.05 was considered statistically significant. RESULTS：The positive rate of EGFR expression in breast invasive ductal carcinoma was 48.7% which was significantly higher than that in invasive lobular carcinoma (24.0%) and fibroadenoma (16.7%) (P<0.01). The positive rate of HER- 2 expression in breast invasive ductal carcinoma was 27.8% which was significantly higher than that in invasive lobular carcinoma (8.0%) and fibroadenoma (6.7%) (P=0.002). In invasive ductal and lobular carcinomas of the breasts，the EGFR positive rate gradually increased with the increase of HER-2 score grade，and the EGFR positive rate was positively correlated with HER-2 score grade (r=1.000， P<0.05)， and the positive rate of EGFR was positively correlated with the expression of HER-2 (r=1.000，P<0.05). The positive rate of EGFR in HER-2 overexpression and TNBC was significantly higher than that in Luminal A and Luminal B， and Luminal B (HER-2 ⁺) than Luminal B (HER-2^-). CONCLUSION：The positive rates of EGFR and HER-2 were significantly increased in invasive cholangiocarcinoma of the breasts，and the positive rate of EGFR was positively correlated with the grade and positive rate of HER-2. EGFR was significantly elevated in HER-2-overexpressing and TNBC which would provide clues and evidence for targeted drug therapy for HER-2 positive breast cancers and triple negative breast carcinomas.

Key words: breast cancer, invasive ductal carcinoma, epidermal growth factor receptor, human epidermal growth factor receptor 2, immunohistochemisty

中图分类号:

R737.9

郭晓娟, 王金西, 牛广旭, 田云霄. EGFR与HER-2在不同分子类型乳腺癌中的表达及其相关性分析[J]. 癌变·畸变·突变, 2022, 34(2): 119-123,148.

GUO Xiaojuan, WANG Jinxi, NIU Guangxu, TIAN Yunxiao. Expression and correlation analyses of EGFR and HER-2 in different types of breast cancers[J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2022, 34(2): 119-123,148.

参考文献

[1] World Health Organization. Global Cancer Observatory(GCO): Cancer Today[EB/OL]. [2020-04-01]. https://gco.iarc.fr.
[2] 张雪, 董晓平, 管雅喆, 等. 女性乳腺癌流行病学趋势及危险因素研究进展[J]. 肿瘤防治研究, 2021, 48(1): 87-92.
[3] JUTTEN B, ROUSCHOP K M A. EGFR signaling and autophagy dependence for growth, survival, and therapy resistance[J]. Cell Cycle, 2014, 13(1): 42-51.
[4] 杨伟斌, 刘志毅, 曹宽, 等. 表皮生长因子受体家族特点及与肿瘤关系的研究进展[J]. 现代肿瘤医学, 2019, 27(2): 346- 351.
[5] 詹琦, 周晟, 娄丽萍. EGFR, HER2和HER3在胆管癌中的表达及预后价值[J]. 实用肿瘤学杂志, 2019, 33(6): 491-496.
[6] 吕燕萍, 吴传城, 杨双凤, 等. 胃癌差异表达miRNA及其相关基因的单核苷酸多态性与胃癌预后的相关性研究[J]. 癌变· 畸变·突变, 2020, 32(5): 380-386.
[7] FENG K C, GUO Y L, DAI H R, et al. Chimeric antigen receptor-modified T cells for the immunotherapy of patients with EGFR-expressing advanced relapsed/refractory non-small cell lung cancer[J]. Sci China Life Sci, 2016, 59(5): 468- 479.
[8] 宋欣, 吕亚莉, 李向红. EGFR和Her-2蛋白表达及基因扩增的应用研究[J]. 诊断病理学杂志, 2014, 21(3): 175-178.
[9] 夏红强, 何建蓉. Ki-67、EGFR、HER-2和p53在乳腺癌中的表达及其相关性[J]. 临床肿瘤学杂志, 2011, 16(2): 139-143.
[10] ARAKI K, MIYOSHI Y. Mechanism of resistance to endocrine therapy in breast cancer: the important role of PI3K/Akt/mTOR in estrogen receptor-positive, HER2-negative breast cancer[J]. Breast Cancer, 2018, 25(4): 392-401.
[11] HEDNER C, BORG D, NODIN B, et al. Expression and prognostic significance of human epidermal growth factor receptors 1, 2 and 3 in oesophageal and gastric adenocarcinomas preneoadjuvant and postneoadjuvant treatment[J]. J Clin Pathol, 2018, 71(5): 451-462.
[12] 汪中明, 周怀英, 吴华玲, 等. 表皮生长因子受体蛋白与临床病理特征对乳腺癌新辅助化疗效果和预后的影响[J]. 河北医药, 2020, 42(3): 325-329.
[13] 杨悦, 万义增, 陈素贤, 等. 结直肠癌组织中EGFR及HER-2的表达及临床意义[J]. 临床与实验病理学杂志, 2015, 31(6): 615-618.
[14] 向青林, 张伟. HER2、EGFR、VEGFR在胃印戒细胞癌中的表达及其临床意义[J]. 医学信息, 2020, 33(6): 87-89.
[15] 段海波, 胡倩, 林颖欣, 等. 曲妥珠单抗联合拉帕替尼及多西紫杉醇一线治疗HER-2阳性晚期乳腺癌的安全性和有效性[J]. 现代肿瘤医学, 2020, 28(18): 3159-3163.
[16] 郭艳, 张长庆. 靶向HER2/EGFR分子双特异性单链抗体的构建及其体内外抗乳腺癌的研究[J]. 检验医学与临床, 2018, 15(19): 2887-2891.
[17] ISHITHA G, MANIPADAM M T, BACKIANATHAN S, et al. Clinicopathological study of triple negative breast cancers[J]. J Clin Diagn Res, 2016, 10(9): EC05-EC09.
[18] 李星枝, 王舰梅, 肖秀丽, 等. GATA-3和 EGFR在乳腺癌中表达的相关性及其与分子亚型、临床病理资料的关系[J]. 川北医学院学报, 2021, 36(4): 414-418.
[19] 马阳, 吴娟, 纪晓坤, 等. 沉默表皮生长因子受体的表达对肺腺癌A549细胞自噬的影响[J]. 癌变·畸变·突变, 2019, 31(5): 347-351, 358.
[20] 李杰, 李诗, 李芳, 等. 三阴型乳腺癌中AR、SOX10、EGFR和PD-L1的表达及临床意义[J]. 临床与实验病理学杂志, 2021, 37(3): 344-347. resistance[J]. Cell Cycle, 2014, 13(1): 42-51.
[4] 杨伟斌, 刘志毅, 曹宽, 等. 表皮生长因子受体家族特点及与肿瘤关系的研究进展[J]. 现代肿瘤医学, 2019, 27(2): 346- 351.
[5] 詹琦, 周晟, 娄丽萍. EGFR, HER2和HER3在胆管癌中的表达及预后价值[J]. 实用肿瘤学杂志, 2019, 33(6): 491-496.